{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:35Z","timestamp":1740106895195,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00277-021-04604-x","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T03:24:02Z","timestamp":1627615442000},"page":"2547-2556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catello","family":"Califano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Palombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofya","family":"Kovalchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bonfichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Rodari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Chimienti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Balzarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sorasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Ciammella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Chauvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"issue":"18","key":"4604_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","volume":"35","author":"S Sasse","year":"2017","unstructured":"Sasse S, Br\u00f6ckelmann PJ, Goergen H, Pl\u00fctschow A, M\u00fcller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35(18):1999\u20132007. https:\/\/doi.org\/10.1200\/JCO.2016.70.9410","journal-title":"J Clin Oncol"},{"issue":"19","key":"4604_CR2","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa064601","volume":"357","author":"C Ferm\u00e9","year":"2007","unstructured":"Ferm\u00e9 C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van\u2019t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divin\u00e9 M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vi\u00e9 B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease. N Engl J Med 357(19):1916\u201327. https:\/\/doi.org\/10.1056\/NEJMoa064601","journal-title":"N Engl J Med"},{"issue":"19","key":"4604_CR3","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin\u2019s Lymphoma Study Group (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 21(19):3601\u20138. https:\/\/doi.org\/10.1200\/JCO.2003.03.023","journal-title":"J Clin Oncol"},{"key":"4604_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/blood.V126.23.580.580","volume":"126","author":"P Borchmann","year":"2015","unstructured":"Borchmann P, Eichenauer DA, Pluetschow A (2015) Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood 126:580. https:\/\/doi.org\/10.1182\/blood.V126.23.580.580","journal-title":"Blood"},{"issue":"Suppl 4","key":"4604_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/annonc\/7.suppl_4.S95","volume":"7","author":"D Hasenclever","year":"1996","unstructured":"Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin\u2019s disease. German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol 7(Suppl 4):95\u201398. https:\/\/doi.org\/10.1093\/annonc\/7.suppl_4.S95","journal-title":"Ann Oncol"},{"issue":"1","key":"4604_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bjh.12862","volume":"166","author":"F Russo","year":"2014","unstructured":"Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A (2014) A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol 166(1):118\u2013129. https:\/\/doi.org\/10.1111\/bjh.12862","journal-title":"Br J Haematol"},{"issue":"27","key":"4604_CR7","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich HT, Diehl V, G\u00f6rgen H, Pabst T, Markova J, Debus J, Ho A, D\u00f6rken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, D\u00f6hner H, Borchmann P, M\u00fcller-Hermelink HK, M\u00fcller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199\u20134206. https:\/\/doi.org\/10.1200\/JCO.2010.29.8018","journal-title":"J Clin Oncol"},{"key":"4604_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","volume":"81","author":"C Ferm\u00e9","year":"2017","unstructured":"Ferm\u00e9 C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Bri\u00e8re J, Henry-Amar M, European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Grouped\u2019\u00c9tude des Lymphomes de l\u2019Adulte (2017) ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d\u2019\u00c9tude des Lymphomes de l\u2019Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer 81:45\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.005","journal-title":"Eur J Cancer"},{"issue":"9","key":"4604_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow B, Pl\u00fctschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A (2012) Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907\u2013913. https:\/\/doi.org\/10.1200\/JCO.2011.38.5807","journal-title":"J Clin Oncol"},{"key":"4604_CR10","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35:1786\u20131794. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"},{"issue":"13","key":"4604_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131(13):1456\u20131463. https:\/\/doi.org\/10.1182\/blood-2017-07-795476","journal-title":"Blood"},{"key":"4604_CR12","unstructured":"Andr\u00e9 ISHL11. 2018 Available at: https:\/\/www.hodgkinsymposium.org\/videos (accessed 13 May 2020)."},{"issue":"9","key":"4604_CR13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","volume":"51","author":"JJ Cerci","year":"2010","unstructured":"Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J Jr, Buccheri V, Meneghetti JC (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51(9):1337\u20131343. https:\/\/doi.org\/10.2967\/jnumed.109.073197","journal-title":"J Nucl Med"},{"key":"4604_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","volume":"2009","author":"ES Jaffe","year":"2009","unstructured":"Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523\u2013531. https:\/\/doi.org\/10.1182\/asheducation.V2009.1.523.0010523","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"4604_CR15","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, von Tresckow B, B\u00f6ll B, Meissner J, Glunz A, Diehl V, Eich HT, Engert A, Borchmann P (2013) Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol 24(12):3070\u20133076. https:\/\/doi.org\/10.1093\/annonc\/mdt413","journal-title":"Ann Oncol"},{"issue":"2","key":"4604_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","volume":"88","author":"T Girinsky","year":"2008","unstructured":"Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P, EORTC-GELA Lymphoma Group (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2008.05.012","journal-title":"Radiother Oncol"},{"issue":"27","key":"4604_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol de M\u00e9dula\u00d3sea; German High-Grade Lymphoma Study Group; German Hodgkin\u2019s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"4604_CR18","unstructured":"CTCAE version 4.0. Available at http:\/\/ctep.cancer.gov\/reporting\/ctc.html (Accessed 13 May 2020)."},{"key":"4604_CR19","unstructured":"Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In: Hellman S, De vita V, Rosenbergs SA (Eds): Important Advance in Oncology. Lippincott, Philadelphia, PA, USA, 1988, 121\u2013124."},{"issue":"5","key":"4604_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.04.021","volume":"92","author":"G Simontacchi","year":"2015","unstructured":"Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U (2015) Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy. Int J Radiat Oncol Biol Phys 92(5):1077\u20131083. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4604_CR21","unstructured":"Fleiss JL. Statistical Methods for Rates and Proportions, 1981, pp. 13\u201315."},{"key":"4604_CR22","doi-asserted-by":"crossref","unstructured":"Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Perrot A, Specht L, Touati M, Eisenmann JC, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Bellei M, Traverse-Glehen A, Copie C, Hutchings M, Versari A, Meignan M, Federico M, Andre M (2017) PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of breach, a randomized phase II trial of Lysa-FIL-EORTC Intergroup. Blood 130(Supplement 1):736 abstract 624.","DOI":"10.1182\/blood.V130.Suppl_1.736.736"},{"issue":"7","key":"4604_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood.2019001272","volume":"134","author":"JS Abramson","year":"2019","unstructured":"Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM (2019) Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 134(7):606\u2013613. https:\/\/doi.org\/10.1182\/blood.2019001272","journal-title":"Blood"},{"issue":"4","key":"4604_CR24","first-page":"475","volume":"91","author":"A Gallamini","year":"2006","unstructured":"Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin\u2019s disease. Haematologica 91(4):475\u2013481","journal-title":"Haematologica"},{"issue":"24","key":"4604_CR25","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D\u2019Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746\u20133752. https:\/\/doi.org\/10.1200\/JCO.2007.11.6525","journal-title":"J Clin Oncol"},{"issue":"1","key":"4604_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D\u2019Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52\u201359. https:\/\/doi.org\/10.1182\/blood-2005-06-2252","journal-title":"Blood"},{"issue":"17","key":"4604_CR27","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O\u2019Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372(17):1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"issue":"10","key":"4604_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","volume":"132","author":"DJ Straus","year":"2018","unstructured":"Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Sch\u00f6der H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132(10):1013\u20131021. https:\/\/doi.org\/10.1182\/blood-2018-01-827246","journal-title":"Blood"},{"key":"4604_CR29","doi-asserted-by":"publisher","unstructured":"Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5(5):CD007941. doi: https:\/\/doi.org\/10.1002\/14651858.CD007941.pub3.","DOI":"10.1002\/14651858.CD007941.pub3"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T08:12:37Z","timestamp":1631607157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4604"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04604-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical committees of the participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent for the inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agreed to submit the current version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}